Recombinant Cyno/Rhesus APRIL/TNFSF13 HA Tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11778-AP

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11778-AP-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Conjugate

Unconjugated

Applications

Bioactivity

View all APRIL/TNFSF13 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived cynomolgus monkey APRIL/TNFSF13 protein
HA
(YPYDVPDYA)		 GCN4-IZ GS Linker Cyno/Rhesus APRIL
(Ala105 - Leu250)
Accession #
XP_005582818.1
N-terminus C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Tyr of HA tag

Predicted Molecular Mass

22 kDa

SDS-PAGE

24-28 kDa, under reducing conditions.

Activity

Measured in a cell proliferation assay using anti-IgM stimulated mouse B cells.
The ED50 for this effect is 2.50-30.0 ng/mL in the presence of goat anti-mouse IgM.

Scientific Data Images for Recombinant Cyno/Rhesus APRIL/TNFSF13 HA Tag Protein, CF

Recombinant Cyno/Rhesus APRIL/TNFSF13 HA Tag Protein Bioactivity.

Measured in a cell proliferation assay using anti-IgM stimulated mouse B cells. The ED50 for this effect is 2.50-30.0 ng/mL in the presence of goat anti-mouse IgM.

Recombinant Cyno/Rhesus APRIL/TNFSF13 HA Tag Protein SDS-PAGE.

2 μg/lane of Recombinant Cyno/Rhesus APRIL/TNFSF13 HA Tag Protein (Catalog # 11778-AP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 24-28 kDa, under reducing conditions.

Formulation, Preparation and Storage

11778-AP
Formulation Lyophilized from a 0.2 μm filtered solution in Tris and NaCl with Trehalose.
Reconstitution Reconstitute at 200 μg/mL in water.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: APRIL/TNFSF13

APRIL (a proliferation-inducing ligand), also known as TNFSF13, TALL2, TRDL1, and CD256, is a member of the TNF ligand superfamily (1). It is synthesized as a 32 kDa proprotein which is cleaved by furin in the Golgi to release the active 17 kDa soluble molecule (2-4). Secreted cyno/rhesus APRIL, which consists almost entirely of a single TNF homology domain, shares 98.6% amino acid sequence identity with human and rat APRIL. Both APRIL and its close relative BAFF bind and signal through the TNF superfamily receptors TACI and BCMA, while BAFF additionally functions through BAFF R (2, 5, 6). APRIL binds to heparan sulfate proteoglycans (HSPGs) independently of its binding to TACI and BCMA (6, 7). The interaction with HSPGs induces APRIL oligomerization, and this augments TACI-, or BMCA-mediated effects (7, 8). HSPGs are also critical for the tumor growth-promoting effects attributed to APRIL (6). APRIL can form bioactive heterotrimers with BAFF, and these circulate in the serum of patients with rheumatic immune disorders (10). TWE-PRIL is a bioactive hybrid protein produced by gene splicing. It consists of the intracellular domain, transmembrane segment, and stalk region of TWEAK fused to the TNF homology domain of APRIL (11). TWE-PRIL is expressed in monocytes and activated T cells and, in contrast to APRIL, is presented on the cell surface (11). APRIL enhances the proliferation and survival of plasma cells and also promotes T cell-dependent humoral responses (2, 12, 13). In the context of autoimmune disorders, however, APRIL can inhibit pathologic humoral responses as well as disease progression (14). Its expression by CD4+ T cells inhibits the production of Th2 cytokines and allergic inflammation (15). APRIL levels are elevated in the serum during coronary artery disease (16), and it is also elevated in many cancers primarily due to expression by tumor-infiltrating neutrophils (4, 7, 17).

References

  1. Planelles, L. et al. (2008) Curr. Mol. Med. 8:829.
  2. Yu, G. et al. (2000) Nat. Immunol. 1:252.
  3. Lopez-Fraga, M. et al. (2001) EMBO Reports 2:945.
  4. Kelly, K. et al. (2000) Cancer Res. 60:1021.
  5. Day, E.S. et al. (2005) Biochemistry 44:1919.
  6. Bossen, C. et al. (2006) J. Biol. Chem. 281:13964.
  7. Hendriks, J. et al. (2005) Cell Death Differ. 12:637.
  8. Schwaller, J. et al. (2007) Blood 109:331.
  9. Ingold, K. et al. (2005) J. Exp. Med. 201:1375.
  10. Roschke, V. et al. (2002) J. Immunol. 169:4314.
  11. Pradet-Balade, B. et al. (2002) EMBO J. 21:5711.
  12. Benson, M.J. et al. (2008) J. Immunol. 180:3655.
  13. He, B. et al. (2004) J. Immunol. 172:3268.
  14. Fernandez, L. et al. (2012) Ann. Rheum. Dis. 72:1367.
  15. Xiao, Y. et al. (2011) Eur. J. Immunol. 41:164.
  16. Sandberg, W.J. et al. (2009) Thromb. Haemost. 102:704.
  17. Mhawech-Fauceglia, P. et al. (2008) Eur. J. Cancer 44:2097.

Long Name

A Proliferation-inducing Ligand

Alternate Names

CD256, TALL2, TNFSF13, TRDL1, ZTNF2

Entrez Gene IDs

8741 (Human); 69583 (Mouse); 287437 (Rat); 102126587 (Cynomolgus Monkey)

Gene Symbol

TNFSF13

Additional APRIL/TNFSF13 Products

Product Documents for Recombinant Cyno/Rhesus APRIL/TNFSF13 HA Tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Cyno/Rhesus APRIL/TNFSF13 HA Tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2026 Bio-Techne. All Rights Reserved. All trademarks and registered trademarks are the property of Bio-Techne and its brands unless otherwise specified.